Sun Lee

Sun Lee

Auto-generated profile, based on publicly available information

Sun Lee

Analysis Group, Inc., Boston, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2006 in Cancer
Verified
Journal Article
Open access
PDF file
HCHyuck Jae Choi
Hyuck Jae Choi
JRJu-Won Roh
Ju-Won Roh
SSSang Soo Seo
Sang Soo Seo
SLSun Lee
Sun Lee
Jooyoung KimJooyoung Kim
Jooyoung Kim
SPSang-Yoon Park
Sang-Yoon Park
BACKGROUND: The objective of the current study was to determine the accuracy of magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) for detecting lymph node metastases in patients with uterine cervical carcinoma compared with thin‐section histopathologic results from systemic lymphadenectomy.METHODS: Twenty‐two patients with International Federation of Obstetrics and Gynecology (FIGO) Stage IB–IVA cervical carcinoma who underwent both MRI and PET/CT before lymphadenectomy were included in this study. Lymphadenectomy involved removing all visible lymph nodes in the surgical fields. To enable region‐specific comparisons, paraaortic and pelvic lymph nodes were divided into seven regions: the paraaortic area, both common iliac areas, both external iliac areas, and both internal iliac/obturator areas. Histopathologic evaluation of lymph nodes was the diagnostic standard. Chi‐square analysis was used to compare the accuracy of MRI and PET/CT for the detection of metastatic lymph nodes. A P value ≤ 0.05 was considered statistically significant.RESULTS: With MRI, the sensitivity, specificity, and accuracy rates for detecting metastatic lymph nodes in each lymph node group were 30.3% (10 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 72.7% (122 of 154 lymph node groups), respectively; with PET/CT, those rates were 57.6% (19 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 85.1% (131 of 154 lymph node groups), respectively. Statistical analysis showed that PET/CT was more sensitive than MRI (P = 0.026) but that there were no statistical differences noted with regard to specificity (P = 1.000) or accuracy (P = 0.180). Power analysis demonstrated that a sample size of 685 lymph node groups (98 patients) would be necessary to demonstrate that PET/CT was more accurate than MRI (α = 0.05; β = 0.80).CONCLUSIONS: PET/CT was more sensitive than MRI for detecting lymph node metastases in patients with uterine cervical carcinoma. Cancer 2006. © 2006 American Cancer Society.

1 March 2021 in Patient Education and Counseling
Verified
Journal Article
Closed access
ESEmmanuelle Schwartzman
Emmanuelle Schwartzman
SLSun Lee
Sun Lee
ECEunice P. Chung
Eunice P. Chung
ALAnandi V Law
Anandi V Law

23 May 2025 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
MHMin Huang
Min Huang
JXJipan Xie
Jipan Xie
HRHela Romdhani
Hela Romdhani
YSYan Song
Yan Song
SLSun Lee
Sun Lee
MKMatthew S. Kelly
Matthew S. Kelly

10 December 2025 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
JXJipan Xie
Jipan Xie
HRHela Romdhani
Hela Romdhani
YSYan Song
Yan Song
SLSun Lee
Sun Lee
MKMatthew S. Kelly
Matthew S. Kelly
Background Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluate the economic value of pneumococcal vaccines. Objectives This study aimed to synthesize utility values used in CUAs of pneumococcal vaccines in adult populations in North America and Europe and to summarize global utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in adults. Methods Two targeted literature reviews were conducted in June 2024 using MEDLINE to identify CUAs of pneumococcal vaccines and original studies on health utilities for pneumococcal disease and PMS in adults. References from existing literature reviews on QoL associated with pneumococcal disease and CUAs of pneumococcal vaccines were also screened to identify additional original utility studies. Health utility input values applied in the CUAs were summarized, and the original source studies were reviewed. Utility and disutility inputs were converted to QALY decrements using disease durations reported in the CUAs. Methods and utility estimates from original utility studies were summarized for each health state. Results Sixty-five CUAs focusing on adults in North America and Europe were identified. These CUAs frequently reported utility values and QALY decrements. The ranges of reported and derived QALY decrements were 0.006–0.8 for unspecified invasive pneumococcal disease (IPD), 0.0013–0.1759 for meningitis, 0.0010–0.1759 for non-meningitis IPD, 0.0002–0.13 for inpatient pneumonia, and 0.0001–0.0115 for outpatient pneumonia. The ranges of reported utility values for PMS were 0.319–0.83 for neurological deficits and 0.635–0.91 for hearing loss. Twenty-five original utility studies in adults were identified, published between 1993 and 2022. Utility estimates from these studies showed considerable variability, with ranges of − 0.330 to 0.39 for meningitis, − 0.331 to 0.93 for non-meningitis IPD, − 0.054 to 0.71 for inpatient pneumonia, 0.35–0.825 for outpatient pneumonia, 0.217–0.89 for neurological deficits, and 0.433–0.89 for hearing loss. This variability was primarily attributable to differences in case definitions, preference weights, and geographical locations. Conclusions This review identified substantial QoL burden associated with pneumococcal disease and PMS in adults; however, considerable variability in utility estimates exists. Utility inputs in CUAs of pneumococcal vaccines in adults often rely upon assumptions, pediatric studies, or utilities from other diseases, and there is relatively little data on the health utilities of IPD and neurological deficits in adults. Given the importance of health utilities in economic evaluations, CUAs should carefully select utility values by considering methodological robustness, the representativeness of health states, and the time frame over which health utilities are assessed and evaluate alternative sources and assumptions in sensitivity analyses.